Table 2.
Correlation between CTC Baseline Positivity and Clinicopathological Characteristics.
| Characteristic | CK19 Baseline (N=86) |
MGB1 Baseline (N=86) |
||
|---|---|---|---|---|
| N (%) ≥ 2 | p-value* | N (%) ≥ 2 | p-value | |
|
| ||||
| Nodal Status | 0.82 | 0.65 | ||
| Node Negative | 27/43 (63) | 13/43 (30) | ||
| Node Positive | 26/43 (61) | 15/43 (35) | ||
|
| ||||
| Histologic Tumor Grade (Elston/SBR) | (N=69) | 0.71 | (N=69) | 0.48 |
| Well/Intermediate | 12/20 (60) | 7/20 (35) | ||
| Poor | 27/49 (55) | 13/49 (27) | ||
|
| ||||
| Surgery | (N=70) | 0.19 | (N=70) | 0.12 |
| Breast Conserving | 16/22 (73) | 5/22 (23) | ||
| Mastectomy | 27/48 (56) | 20/48 (42) | ||
|
| ||||
| ER/PR Status: | 0.03 | 0.009 | ||
| ER or PgR Positive | 32/44 (73) | 20/44 (46) | ||
| Other | 21/42 (50) | 8/42 (19) | ||
|
| ||||
| # of Metastatic Sites | 0.009 | 0.90 | ||
| < 3 | 25/50 (50) | 16/50 (32) | ||
| ≥ 3 | 28/36 (78) | 12/36 (33) | ||
|
| ||||
| Histology | (N=57) | 0.004 | (N=57) | 0.12 |
| Ductal | 23/48 (48) | 14/48 (29) | ||
| Other | 9/9 (100) | 5/9 (56) | ||
|
| ||||
| Performance Status | 0.15 | 0.66 | ||
| 0 | 27/49 (55) | 15/49 (31) | ||
| 1,2 | 26/37 (70) | 13/37 (35) | ||
|
| ||||
| Menopausal Status | 0.38 | 0.35 | ||
| Pre or <50 yrs | 13/24 (54) | 6/24 (25) | ||
| Post or ≥ 50 yrs | 40/62 (65) | 22/62 (36) | ||
|
| ||||
| Age Group | 0.61** | 0.72** | ||
| < 40 | 6/10 (60) | 4/10 (40) | ||
| 40-49 | 10/17 (59) | 5/17 (29) | ||
| 50-59 | 19/31 (61) | 11/31 (36) | ||
| 60-60 | 14/23 (61) | 6/23 (26) | ||
| 70+ | 4/5 (80) | 2/5 (40) | ||
*
: χ2;
**
: Mantel-Haesnzel; SBR:Scarff-Bloom-Richardson; ER: estrogen receptor; PgR: progesterone receptor